Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China

Sponsor
GlaxoSmithKline
Study ID
NCT04853225
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Prospective observational cohort study — OTHER
    Prospective observational cohort study

Study Details

This is a non-drug interventional cohort study, which aims to investigate the clinical, radiological and biological factors associated with disease progression in COPD in China. Participants will be recruited from multiple hospitals across Guangdong province categorized as Type A hospitals (those at prefecture-level and above) and Type B hospitals (those below prefecture-level).

Key Dates

First listed
Apr 21, 2021
Start date
Apr 22, 2020
Status verified
Jul 2025
Primary completion
Jun 25, 2024
Completion
Jun 25, 2024

Study Design

Enrollment
2,005 participants (actual)

Arms

  • Arm: Main cohort
    COPD, chronic bronchitis and healthy participants (never smoker) from Type A and Type B hospitals will be included.
  • Arm: Sub-cohort
    COPD, chronic bronchitis and healthy participants (never smoker) from selected Type A hospitals will be included.

Primary Outcome Measure

Main Cohort: Change From Baseline in Pre-bronchodilator and Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Month 30 [ Time Frame: Baseline (Day 1 of Month 1) and at Month 30 ]

Find similar trials

Nationwide
COPD trialsPulmonology trialsLung disease trials

Related Studies